Sanity Group, founded in Berlin in 2018, develops medicinal cannabis, wellbeing and cosmetic cannabinoid products and operates brands/subsidiaries such as AVAAY Medical, Vayamed, Endosane Pharmaceuticals and VAAY. The company maintains a large German distribution network of over 2,000 pharmacies and works with approximately 5,000 physicians, holding roughly a 10% share of the German medical cannabis market; its AVAAY medical brand is estimated to be number two. Sanity is participating in a Swiss recreational cannabis pilot in Basel with one store operational and plans to expand its retail footprint in Switzerland. The company intends to invest in proprietary distribution channels to capture new medical consumers and is planning initiatives expected to provide access to over 100,000 patients and support recreational pilot expansion. Sanity’s product mix spans pharmaceuticals, medical cannabis, and wellbeing/cosmetic offerings, and it operates a storage facility near Frankfurt for extracts and flower. Sanity Group develops medicinal cannabis, finished pharmaceuticals, medical products, digital applications, wellbeing products and natural cosmetics that utilize cannabinoids and the endocannabinoid system. The group comprises Vayamed and AVAAY Medical (medicinal cannabis), Endosane Pharmaceuticals (finished pharmaceuticals), Belfry Medical (medical products and digital applications), VAAY (wellbeing) and This Place (natural cosmetics). It operates a production and processing facility for cannabis extracts near Frankfurt am Main and employs around 120 people across medical, consumer health and science functions. Founded in Berlin in 2018, the company aims to improve quality of life through cannabinoid-based products and therapies. Sanity Group plans to use new funding to accelerate growth, enable European expansion and strengthen research and development. The company has raised over $100 million in total funding to date. Sanity Group is a Berlin-based cannabis and digital health startup that builds a cannabis-based platform for mental health and chronic pain management. Its offering includes a medical device and digital therapy diary that tracks administered active ingredients (THC, CBD and other cannabinoids) to quantify dosing. The company closed a $44.2M Series A, bringing total funding to $73M; the round is reported as the largest cannabis funding round in Europe to date. Proceeds will be used to expand the Group’s medical division in Europe and to build an EU‑GMP‑compliant research and production facility near Frankfurt. Management says it is expanding geographically into the Czech Republic and Poland, targeting the U.K., and expects France to open next year. Prior investors include HV Capital, TQ Ventures, Atlantic Food Labs, Cherry Ventures, Bitburger Ventures and SevenVentures, and celebrity angels include will.i.am, Scooter Braun and Alyssa Milano. Sanity Group is a Berlin-based medical cannabis and wellness company operating two business units: Sanatio Pharma, focused on developing new medical cannabis therapies and pharmaceuticals, and VAAY, a consumer wellness brand. The company is fully licensed and currently operational. Founded in 2018 by Finn Hänsel and Fabian Friede, Sanity Group combines medical and consumer wellness offerings. It completed a €20m funding round to support strategic initiatives. The funds will be used to drive projects that expand access to medical and medically-related cannabis products and advance its product programs.

Total raised

$120M

Funding rounds

5

Latest round

Equity

Latest activity

Jun 2024